5 Most Promising Cancer Stocks According to Analysts

4. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Latest Analyst Share Price Upside: 83.11%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a small biotechnology company focusing on treatments for child cancers, tumors, and other ailments. December was a good month for the stock as it was added to the NASDAQ biotechnology index after meeting all the criteria for inclusion.

As of Q3 2023 end, 12 out of the 910 hedge funds profiled by Insider Monkey were the firm’s investors. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s largest hedge fund shareholder is Brian Ashford-Russell and Tim Woolley’s Polar Capital as it owns $11.4 million worth of shares.

Follow Y-Mabs Therapeutics Inc.